Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. ( (JP:130A) ) has shared an announcement.
Veritas In Silico Inc. and Shionogi & Co., Ltd. have announced a significant milestone in their joint drug discovery research targeting mRNA with small molecules. The achievement involves acquiring compounds that selectively inhibit the translation of target proteins, marking progress in developing treatments for diseases previously undruggable by conventional methods. This milestone will result in milestone revenue for Veritas In Silico, which is already accounted for in their FY2025 earnings forecast.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on drug discovery. The company specializes in developing small molecule drugs targeting mRNA, utilizing its proprietary drug discovery platform, ibVIS®. Its market focus includes infectious diseases, psychiatric, and neurological disorders.
Average Trading Volume: 34,239
Technical Sentiment Signal: Sell
See more insights into 130A stock on TipRanks’ Stock Analysis page.